For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
Retatrutide
Triple-Action Metabolic Peptide
Dosage
Quantity
Price
$62.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- Retatrutide 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Retatrutide (Eli Lilly) is a once-weekly triple unimolecular agonist of GIP, GLP-1, and glucagon receptors—i.e., “three-pathway” or “GLP-1++” metabolic engineering, not a separate endogenous “GLP-3” hormone. Summaries below compile sponsor trials (TRIUMPH program, NEJM publications). This listing is research-only and not FDA-approved therapy.
28.7%
Weight loss
Phase 3 TRIUMPH readouts (~68 weeks) at the 12 mg weekly dose in obesity cohorts.
3
Receptor targets
Concurrent GIP, GLP-1, and glucagon receptor activation—distinct from dual GLP-1/GIP molecules.
1× / wk
Dosing
Subcutaneous autoinjector-style administration in development programs.
86%
Liver fat
Phase 2 MASH/NASH-style substudies report deep reductions in hepatic fat fraction (~48 weeks).
5.8k+
Exposure
Cumulative randomized exposure across Lilly-sponsored metabolic trials (rounded).
Development status
Where it stands
- Developer
- Eli Lilly
- Trial umbrella
- TRIUMPH (obesity / OA / cardiometabolic)
- Regulatory outlook
- Filings and PDUFA-style dates evolve—verify Lilly IR & FDA calendars
- This SKU
- Non-pharmaceutical research material unless separately licensed
What researchers observed
Phase 2 dose-response and Phase 3 obesity outcomes (public disclosures)
Phase 3 — TRIUMPH-4 highlight
~71 lbs
Mean weight loss — 12 mg arm (~68 weeks, ~445 adults, baseline ~248 lbs class)
Percent change by arm
Detailed estimands, rescue criteria, and sensitivity analyses appear in NEJM / Lilly press releases—figures here are headline summaries only.
Responder milestones (12 mg)
Depth of weight loss
≥5% is a conventional clinically meaningful threshold; high-dose triple agonism produced bariatric-like responder fractions in public top-line narratives.
Triple vs dual vs single agonists
- Retatrutide (~12 mg, TRIUMPH-style)~28.7%
- Tirzepatide (~15 mg, SURMOUNT-class)~22.5%
- Semaglutide (~2.4 mg, STEP-class)~17%
Different eligibility, background therapy, and visit schedules make naive ranking unreliable—only on-trial randomizations are fair comparisons.
Phase 2 dose ladder (~48 weeks)
NEJM dose-finding obesity cohorts
Clear dose-response: higher weekly exposure → greater mean weight reduction.
Beyond weight loss
Organ-specific and cardiometabolic signals from trial substudies
−86%
Liver fat
~93% normalized hepatic fat in substudy narratives (Nature Medicine).
−2.2%
HbA1c
Majority of diabetic participants reached glycemic targets (Lancet).
72%
Prediabetes reversal
Normoglycemia restoration in cited substudy (NEJM).
−38%
Triglycerides
Pooled / meta-analytic lipid shifts (review context).
Body composition
Fat vs lean partitioning
Like other incretin therapies, absolute lean mass falls with weight but constitutes a minority of total loss—ratio comparable to GLP-1-class agents in DEXA substudies.
Resistance training and adequate protein remain standard mitigation strategies (Lancet Diabetes Endocrinol reviews).
Heart health
Cardiometabolic markers
- Triglycerides↓ ~38%
- LDL cholesterol↓ ~18%
- HDL cholesterol↑ ~12%
- Systolic BP↓ ~7 mmHg
Meta-analytic / trial-aggregate figures—confirm in primary tables.
Joint health
Knee OA pain (TRIUMPH-OA)
75.8%
Relative improvement in pain scores at 12 mg vs baseline narratives
~12% became pain-free at week 68 vs ~4% on placebo in sponsor top-line summaries—verify case definitions in the CSR.
Side effects observed in trials
GI burden typical of incretins; glucagon arm adds unique sensory AEs
Most adverse events are mild–moderate, peak during titration, and improve with continued dosing. Rates below skew toward the 12 mg exposure arm in public tables.
Common GI events
Nausea
MildDiarrhea
MildConstipation
MildVomiting
ModerateUnique signal — dysesthesia
Tingling / burning / numbness reported in ~20.9% of 12 mg participants vs ~0.7% placebo (~30× relative difference in sponsor tables). Usually transient; hypothesized link to glucagon-receptor biology / nerve metabolism—still under characterization.
AE-related discontinuation
- 12 mg18.2%
- 9 mg12.2%
- 4 mg6.8%
- Placebo4.0%
Some withdrawals reflected participant discomfort with rapid weight loss—not only classic intolerance.
Rare serious themes
- Gallstone disease <5% (class effect)
- Pancreatitis <1% — monitor per protocol
- Injection-site reactions <3%
Storage handling reference
Peptide handling
Cold
Follow COA; biologic stability critical.
Reconstitution
Sterile SC prep if applicable.
Light
Protect during aliquoting.
Regulatory
≠ pharmacy pen unless Rx dispensed.
Researcher notes
- Peak AE rates quoted above align with the 12 mg cohort—lower doses are materially gentler in most tables.
- GI symptoms typically attenuate after the first 4–8 weeks once titration stabilizes.
- Glucagon co-agonism differentiates tolerability (dysesthesia, HR/BP nuances) from pure GLP-1 therapy—read glucagon AE sections carefully.
- Triple agonism is not “GLP-3”; always name the three receptors when writing protocols or IRB documents.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.